Entera Bio Ltd. Q1 2025 10-Q Filed
Ticker: ENTX · Form: 10-Q · Filed: May 9, 2025 · CIK: 1638097
| Field | Detail |
|---|---|
| Company | Entera Bio LTD. (ENTX) |
| Form Type | 10-Q |
| Filed Date | May 9, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
Entera Bio Q1 2025 10-Q is in. Financials updated.
AI Summary
Entera Bio Ltd. filed its 10-Q for the period ending March 31, 2025. The filing details financial information for the first quarter of 2025, including changes in retained earnings, accumulated other comprehensive income, additional paid-in capital, and common stock. The company is in the biological products sector and is based in Jerusalem.
Why It Matters
This filing provides investors with the latest financial snapshot of Entera Bio Ltd., crucial for understanding the company's performance and financial health in early 2025.
Risk Assessment
Risk Level: low — This is a routine financial filing (10-Q) and does not contain new material events or significant risk disclosures.
Key Numbers
- 2025-03-31 — End of Reporting Period (Marks the end of the financial quarter being reported.)
- 2025-05-09 — Filing Date (Date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- Entera Bio Ltd. (company) — Filer of the 10-Q
- 2025-03-31 (date) — End of the reporting period
- 2025-05-09 (date) — Filing date
- Jerusalem (location) — Company's business address
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is the first quarter of 2025, ending on March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed with the SEC on May 9, 2025.
What is the primary business of Entera Bio Ltd. according to the filing?
Entera Bio Ltd. is in the business of Biological Products (No Diagnostic Substances).
Where is Entera Bio Ltd. located?
Entera Bio Ltd.'s business address is in Jerusalem.
What financial statement items are detailed for the period ending March 31, 2025?
The filing details changes in Retained Earnings, Accumulated Other Comprehensive Income, Additional Paid-In Capital, and Common Stock for the period.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 9, 2025 regarding Entera Bio Ltd. (ENTX).